Insufficiency of the pituitary gland resulting from central nervous system infiltration in course of non-Hodgkin’s DLBCL lymphoma recurrence

Monika Łubińska¹, Michał Taszner², Piotr Kmiec³, Andrzej Hellmann³, 
Krzysztof Sworczak³

¹Department of Endocrinology and Internal Diseases, Medical University of Gdansk, 
Poland
²Department of Haematology and Transplantology, Medical University of Gdansk, Poland

Introduction

Central nervous system infiltration by lymphoproliferative neoplasms, such as non-Hodgkin lymphomas, may take place as a primary process when the tumour’s mass is found solely in this location, or secondarily, i.e. featuring an extranodal site of a generalised non-Hodgkin’s lymphoma (NHL).

Primary CNS lymphomas are rare diseases with poor prognosis, necessitating radically aggressive treatment [1].

Secondary CNS lymphomas (SCNSL) are defined as NHL present both in and outside of the CNS. Secondary CNS lymphomas may infiltrate meninges, deep brain structures, spinal cord and cerebro-spinal fluid (CSF) [2]. The lesions may be single, diffused or disseminated [3].

Secondary CNS involvement is rarely found on NHL diagnosis (with a case frequency median of 1.1%); more often, patients with NHL recurrence after treatment are affected [4]. A proposed reason for this is the insufficient CNS penetration of 1st-line drugs [5].

Several factors have been identified in assessing the risk of NHL recurrence with CNS involvement that point at clinical situations in which the implementation of prophylactic treatment should be considered. Until now, research has not resulted in a single accepted treatment scheme for SCNSL; thus, treatment often remains individualised.

Hypophysis insufficiency (HI) as a result of neoplasmatic growth is a rare condition. Among primary tumours that yield metastases to the gland, breast and lung cancers are most frequent, and less commonly gastrointestinal tract carcinomas and malignant melanomas are enumerated [6]. Thus far, only a few cases of a primary hypophysis involvement by a primary or secondary NHL have been reported [7–10].

Depending on the time frame and the extent of hypophysis infiltration, as well as the patient’s age, a typical constellation of symptoms of gland insufficiency develop. These may be accompanied by symptoms resulting from hypothalamus and/or optic chiasm involvement [11, 12].

Endocrine insufficiency symptoms presented by a patient with NHL-infiltrated pituitary may be mistakenly considered as being caused by the lymphoma itself or due to the chemotherapy applied against it.

In this article we would like to stress the importance of considering symptoms not only as a consequence of the primary disease or the side-effects of its treatment, but also as symptoms of a secondarily developing pathological process in its course. Attentive patient supervision facilitates the diag-

Key words: pituitary insufficiency, diabetes insipidus, central nervous system infiltration, lymphoma.
nosis of new events triggered by the disease and allows to undertake the correct additional treatment.

Case report

A 59-year-old man was referred to a day ward of the Haematology and Transplantology Clinic of the Medical University of Gdansk hospital due to fatigue (WHO performance status scale score was 2), considerable weight loss, generalised lymphadenopathy and splenomegaly.

Laboratory findings revealed anaemia (haemoglobin value of 8.4 g/dl) and increased lactate dehydrogenase (LDH) level (1089 IU/l). A DLBCL CD20+, CD3– non-Hodgkin lymphoma with a Ki67 index value of 50% was diagnosed in a lymph node histological examination. III S clinical stage of the lymphoma was stated using a computed tomography scan.

Based on the present risk factors of the International Prognostic Index (IPI), i.e. 3, the patient was assigned to the high-medium risk group.

Six cycles of first-line treatment were applied – R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone). A complete remission was achieved, as confirmed in a PET scan.

Eleven months after the treatment in a follow-up PET scan, recurrence of the NHL was suggested, which was confirmed the following month when a SCNSL was also suspected. On admission to the Haematology Clinic the patient complained of headaches, vertigo, imbalance and nausea. These, along with extreme fatigue, were initially recognised as symptoms resulting from general condition worsening due to the progress of the disease.

Secondary peripheral endocrine gland insufficiency symptoms dominated in the clinical presentation, i.e. decreased hypophysis and peripheral hormone deficiencies, i.e. decreased hypophysis insufficiency symptoms.

Type B symptoms were absent.

In 2010 the Polish Lymphoma Research Group published detailed guidelines on diagnostic, prophylactic and therapeutic procedures regarding CNS infiltration of diffuse large B cell lymphomas [15].

Table 1. Results of hormonal, biochemical and osmolal analyses in a patient with pituitary lymphoma infiltration before hormonal substitution

<table>
<thead>
<tr>
<th>Tests and normal ranges</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>TSH (N: 0.34–4.94 mIU/l)</td>
<td>0.06</td>
</tr>
<tr>
<td>fT4 (N: 9.01–19.05 pmol/l)</td>
<td>8.93</td>
</tr>
<tr>
<td>fT3 (N: 2.63–5.7 pmol/l)</td>
<td>2.88</td>
</tr>
<tr>
<td>ACTH (N: &lt; 46 pg/ml)</td>
<td>&lt; 10</td>
</tr>
<tr>
<td>Cortisol 8.00 (N: 116–1060 nmol/l)</td>
<td>28.7</td>
</tr>
<tr>
<td>Cortisol 20.00 (N: 47–458 nmol/l)</td>
<td>61.4</td>
</tr>
<tr>
<td>FSH (N: 1.3–13.5 mIU/ml)</td>
<td>0.41</td>
</tr>
<tr>
<td>LH (N: 1.8–8.16 U/l)</td>
<td>&lt; 0.7</td>
</tr>
<tr>
<td>Testosterone (N: 5.76–28.14 nmol/l)</td>
<td>0.43</td>
</tr>
<tr>
<td>Serum osmolality (N: 270–295 mOsm/l)</td>
<td>301</td>
</tr>
<tr>
<td>Urine osmolality (N: 250–1300 mOsm/l)</td>
<td>186</td>
</tr>
<tr>
<td>Na (N: 135–145 mEq/l)</td>
<td>152</td>
</tr>
<tr>
<td>K (N: 3.5–5.1 mEq/l)</td>
<td>4.2</td>
</tr>
<tr>
<td>Urine specific gravity (1.018–1.030 kg/l)</td>
<td>1.001</td>
</tr>
</tbody>
</table>

Discussion

Central nervous system infiltration in the course of NHL is a rare event and can be used to be estimated 5 to 10% of cases [2, 13, 14]; however, there are new reports.

In 2010 the Polish Lymphoma Research Group published detailed guidelines on diagnostic, prophylactic and therapeutic procedures regarding CNS involvement of diffuse large B cell lymphomas [15].
Boehme et al. analysed 1222 elderly patients with aggressive B-cell lymphoma (mostly DLBCL), treated with courses of CHOP or R-CHOP. The number of patients who developed CNS disease was fifty-eight, which constituted 4.8% of the analysed patients [16].

In recently published papers by Schmitz et al., the authors analysed 2210 younger patients with aggressive B-cell lymphoma treated in various studies for the incidence and risk factors of CNS infiltration [17]. Fifty-six of those patients (2.6%) developed CNS disease. According to their conclusions, patients with higher age-adjusted International Prognostic Index (aaIPI 2 or 3) showed higher risk (4.2–9.7%) and no significant reduction of CNS disease with rituximab, while patients with aaIPI 0 or 1 showed a low risk for CNS disease (0–0.5%) and rituximab decreased the risk. Another conclusion was that CNS prophylaxis with intrathecal methotrexate was of no significant benefit.

Central nervous system disease is characterised by a very poor prognosis [2]. Certain risk factors on NHL diagnosis may suggest prophylactic treatment against CNS involvement by applying intrathecal or high-dose systemic chemotherapy [18]. These factors include advance stage of the disease, two or more extranodal sites involved, patient age less than 60, increased serum LDH concentration, presence of B-symptoms, involvement of bone marrow, testicles, spinal column, paranasal sinuses, orbits, breasts or retroperitoneal lymph nodes, decreased albumin concentration or some specific histopathological subtypes of NHL [15–20]. Some of the above risk factors were present in our patient, and the application of prophylactic treatment penetrating to the CNS may have been beneficial.

Typical NHL symptoms such as weakness, fatigue, night sweats, fever and weight loss in case of CNS involvement can be even more intense. Most frequent CNS-infiltration related symptoms are cephalgia, seizures, plegias and paralyses, paresthesias as well as psychiatric disorders and quantitative and qualitative consciousness disturbances [2, 3]. Furthermore, adverse chemo- and radiotherapy effects may mask symptoms due to the decline of neoplasm-infiltrated structures, which may then lead astray the attention of the physician.

Diagnosed relatively rarely, metastases to the hypophysis usually affect adults and elderly patients. Clinically most frequently reported are diabetes insipidus resulting from hypothalamus or posterior hypophysis lobe involvement, hyperprolactinaemia due to infundibular stem damage or visual field defect caused by optic chiasm involvement, and much less commonly posterior and anterior hypophysis lobe disorders [7, 21].

Primary CNS lymphomas and secondary CNS infiltration by NHLs occur rarely. Symptoms resulting from hypophysis function impairment – particularly unspecific symptoms such as headaches, weakness, weight loss, apathy and nausea – may be associated with the disease itself or explained as a consequence of intensive treatment while their true cause remains unnoticed. This in turn largely delays the implementation of hormonal substitution and reduces the therapeutic efficacy as a whole [9, 10, 21]. Consequently, CNS infiltrations are often found only in post-mortem examinations.

Conclusions

The case reported here illustrates the necessity of a wide perspective when considering a patient with a neoplastic disease. Accepting the most straightforward explanation of the observed symptoms without an in-depth analysis of all data may lead to a delay of serious but treatable complications.

Disease progression was observed in our patient with CNS infiltration, and he developed complete bi-lobular hypophysis insufficiency symptoms.

Adequate diagnosis enabled application of hormonal substitution treatment that prevented life-threatening endocrine crises (adrenal, thyroid). The patient was able to enjoy a satisfactory quality of life and continue haematological treatment.

The issue of CNS prophylaxis of patients with aggressive B-cell lymphoma, when the identified risk factors mentioned above are present, is still difficult and requires further research and precise guidelines.

Authors declare no conflict of interest.

References


Address for correspondence
Monika Łubińska
Department of Endocrinology and Internal Diseases
University Clinical Centre
Medical University of Gdansk
Debinki 7
80-952 Gdansk
e-mail: mlubinska@gumed.edu.pl

Submitted: 13.02.2012
Accepted: 8.05.2013